Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus EGFR-TKI in advanced EGFR-mutant non-squamous non-small cell lung cancer
ChiCTR1900020825Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Inner Mongolia Medical University
- Start
- Feb 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib in non-small cell lung cancer (NSCLC), sponsored by Affiliated Hospital of Inner Mongolia Medical University. Primary endpoint: Progression-free survival. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
Rivoceranib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900020825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020825.